These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 10990198

  • 1. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
    Brimer C, Dalton JT, Zhu Z, Schuetz J, Yasuda K, Vanin E, Relling MV, Lu Y, Schuetz EG.
    Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
    [Abstract] [Full Text] [Related]

  • 2. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
    Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y.
    Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
    [Abstract] [Full Text] [Related]

  • 3. Modulation of P450 CYP3A4-dependent metabolism by P-glycoprotein: implications for P450 phenotyping.
    Baron JM, Goh LB, Yao D, Wolf CR, Friedberg T.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):351-8. PubMed ID: 11160617
    [Abstract] [Full Text] [Related]

  • 4. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
    Katoh M, Nakajima M, Yamazaki H, Yokoi T.
    Eur J Pharm Sci; 2001 Feb; 12(4):505-13. PubMed ID: 11231118
    [Abstract] [Full Text] [Related]

  • 5. CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4.
    Lee CA, Kadwell SH, Kost TA, Serabjit-Singh CJ.
    Arch Biochem Biophys; 1995 May 10; 319(1):157-67. PubMed ID: 7771780
    [Abstract] [Full Text] [Related]

  • 6. P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification.
    Chan LM, Cooper AE, Dudley AL, Ford D, Hirst BH.
    J Drug Target; 2004 May 10; 12(7):405-13. PubMed ID: 15621665
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Development of Caco-2 cells co-expressing CYP3A4 and NADPH-cytochrome P450 reductase using a human artificial chromosome for the prediction of intestinal extraction ratio of CYP3A4 substrates.
    Takenaka T, Kazuki K, Harada N, Kuze J, Chiba M, Iwao T, Matsunaga T, Abe S, Oshimura M, Kazuki Y.
    Drug Metab Pharmacokinet; 2017 Feb 10; 32(1):61-68. PubMed ID: 28139373
    [Abstract] [Full Text] [Related]

  • 15. Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells.
    Bertilsson PM, Olsson P, Magnusson KE.
    J Pharm Sci; 2001 May 10; 90(5):638-46. PubMed ID: 11288108
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes.
    Yamazaki H, Nakajima M, Nakamura M, Asahi S, Shimada N, Gillam EM, Guengerich FP, Shimada T, Yokoi T.
    Drug Metab Dispos; 1999 Sep 10; 27(9):999-1004. PubMed ID: 10460798
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.